Rapidly Advancing Five IRD Programs with Four Clinical Data Readouts Expected in 2027 RDH12, MERTK and RHO Programs Expected to Enter Clinical Testing o...
VIVEbiotech, a leading lentiviral vector Contract Development and Manufacturing Organization (CDMO), underscored its industry leadership in the dev...
Clinical Trial approval for TCX-001 is another significant development milestone for T-CURX and marks the transition of T-CURX from a pre-clinical to a...
-Parse Biosciences, the leading provider of scalable and accessible single cell sequencing solutions, announced an alliance with bit.bio to create a comp...
G-Link enables targeted in vivo delivery and streamlines ex vivo workflows without lentiviral vector reengineering G-Link supports multiple delivery...
United Immunity, Co., Ltd., a biotechnology company developing its proprietary Myeloid Targeting Platform™ for therapeutic in vivo engineerin...
Endeavor® Live Cell enables rapid kinetic imaging across large scale screening campaigns, generating the cellular data needed to support Lab-in-...
The state-of-the-art facility enhances support for complex modalities across all phases of drug development Key facts Thermo Fisher opens new bioanal...
VYVGART and VYVGART Hytrulo are the first and only approved treatments for all serotypes of adult patients living with gMG – anti-AChR-Ab positiv...
To address the critical need for accelerated decision-making and de-risked progression from discovery to Chemistry, Manufacturing, and Controls (CMC) in ...
New Gibco™ CTS™ DynaXS™ Single Use Bioreactor supports flexible, cGMP-ready cell expansion from process development to clinical p...
Valerio Therapeutics (FR0010095596 – ALVIO), a biotechnology company specializing in the development of technology platforms dedicated to the targe...
Kytopen partners with T-CURX and the Fraunhofer Institute for Cell Therapy and Immunology (IZI) in Würzburg and Leipzig, Germany to establish a jo...
AviadoBio Ltd. (“AviadoBio”) and Apertura Gene Therapy (“Apertura”), a biotechnology company developing next-generation AAV capsi...
© 2026 Biopharma Boardroom. All Rights Reserved.
